Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
Open Access
- 29 January 1999
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 79 (5) , 882-887
- https://doi.org/10.1038/sj.bjc.6690141
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Renal toxicity of the anticancer drug fostriecinCancer Chemotherapy and Pharmacology, 1998
- Topoisomerase Poisons: Harnessing the Dark Side of Enzyme MechanismJournal of Biological Chemistry, 1995
- MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoringComputers in Biology and Medicine, 1992
- Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistanceCancer Chemotherapy and Pharmacology, 1991
- Catalytic function of DNA topoisomerase IIBioEssays, 1991
- Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in ratsFundamental and Applied Toxicology, 1990
- Influence of Docosahexaenoic Acid on Cisplatin Resistance in a Human Small Cell Lung Carcinoma Cell LineJNCI Journal of the National Cancer Institute, 1989
- Inhibition of type II topoisomerase by fostriecinBiochemical Pharmacology, 1988
- In Vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assayEuropean Journal of Cancer and Clinical Oncology, 1986
- TRANSPORT OF THE ANTITUMOR ANTIBIOTIC CL-920 INTO L1210 LEUKEMIA-CELLS BY THE REDUCED FOLATE CARRIER SYSTEM1984